The impact of lung cancer on survival of idiopathic pulmonary fibrosis

Sara Tomassetti, Christian Gurioli, Jay H. Ryu, Paul A. Decker, Claudia Ravaglia, Paola Tantalocco, Matteo Buccioli, Sara Piciucchi, Nicola Sverzellati, Alessandra Dubini, Giampaolo Gavelli, Marco Chilosi, Venerino Poletti

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Background: Lung cancer (LC) is frequently associated with idiopathic pulmonary fibrosis (IPF). Despite this well-known association, the outcome of LC in patients with IPF is unclear. The objective of this study was to evaluate the impact of LC on survival of patients with associated IPF. Methods: A total of 260 patients with IPF were reviewed, and 186 IPF cases had complete clinical and follow-up data. Among these, five cases were excluded because LC was radiologically suspected but not histologically proven. The remaining 181 cases were categorized in two groups: 23 patients with biopsy-proven LC and IPF (LC-IPF) and 158 patients with IPF only (IPF). Survival and clinical characteristics of the two groups were compared. Results: Prevalence of histologically proven LC was 13%, and among those with LC-IPF cumulative incidence at 1 and 3 years was 41% and 82%. Patients with LC were more frequently smokers (91.3% vs 71.6%, P = .001), with combined pulmonary fibrosis and emphysema (52% vs 32%, P = .052). Survival in patients with LC-IPF was significantly worse than in patients with IPF without LC (median survival, 38.7 months vs 63.9 months; hazard ratio = 5.0; 95% CI, 2.91-8.57; P <.001). Causes of death in the study group were respiratory failure in 43% of patients, LC progression in 13%, and LC treatment-related complications in 17%. Conclusions: In patients with IPF, LC has a significant adverse impact on survival. Diagnosis and treatment of LC in IPF are burdened by an increased incidence of severe complicating events, apparently as lethal as the cancer itself.

Original languageEnglish
Pages (from-to)157-164
Number of pages8
JournalChest
Volume147
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Idiopathic Pulmonary Fibrosis
Lung Neoplasms
Survival
Pulmonary Emphysema
Pulmonary Fibrosis
Incidence
Respiratory Insufficiency

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Tomassetti, S., Gurioli, C., Ryu, J. H., Decker, P. A., Ravaglia, C., Tantalocco, P., ... Poletti, V. (2015). The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest, 147(1), 157-164. https://doi.org/10.1378/chest.14-0359

The impact of lung cancer on survival of idiopathic pulmonary fibrosis. / Tomassetti, Sara; Gurioli, Christian; Ryu, Jay H.; Decker, Paul A.; Ravaglia, Claudia; Tantalocco, Paola; Buccioli, Matteo; Piciucchi, Sara; Sverzellati, Nicola; Dubini, Alessandra; Gavelli, Giampaolo; Chilosi, Marco; Poletti, Venerino.

In: Chest, Vol. 147, No. 1, 01.01.2015, p. 157-164.

Research output: Contribution to journalArticle

Tomassetti, S, Gurioli, C, Ryu, JH, Decker, PA, Ravaglia, C, Tantalocco, P, Buccioli, M, Piciucchi, S, Sverzellati, N, Dubini, A, Gavelli, G, Chilosi, M & Poletti, V 2015, 'The impact of lung cancer on survival of idiopathic pulmonary fibrosis', Chest, vol. 147, no. 1, pp. 157-164. https://doi.org/10.1378/chest.14-0359
Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015 Jan 1;147(1):157-164. https://doi.org/10.1378/chest.14-0359
Tomassetti, Sara ; Gurioli, Christian ; Ryu, Jay H. ; Decker, Paul A. ; Ravaglia, Claudia ; Tantalocco, Paola ; Buccioli, Matteo ; Piciucchi, Sara ; Sverzellati, Nicola ; Dubini, Alessandra ; Gavelli, Giampaolo ; Chilosi, Marco ; Poletti, Venerino. / The impact of lung cancer on survival of idiopathic pulmonary fibrosis. In: Chest. 2015 ; Vol. 147, No. 1. pp. 157-164.
@article{e5cc9fbbce0b4839bc3e616ff8ff0cbf,
title = "The impact of lung cancer on survival of idiopathic pulmonary fibrosis",
abstract = "Background: Lung cancer (LC) is frequently associated with idiopathic pulmonary fibrosis (IPF). Despite this well-known association, the outcome of LC in patients with IPF is unclear. The objective of this study was to evaluate the impact of LC on survival of patients with associated IPF. Methods: A total of 260 patients with IPF were reviewed, and 186 IPF cases had complete clinical and follow-up data. Among these, five cases were excluded because LC was radiologically suspected but not histologically proven. The remaining 181 cases were categorized in two groups: 23 patients with biopsy-proven LC and IPF (LC-IPF) and 158 patients with IPF only (IPF). Survival and clinical characteristics of the two groups were compared. Results: Prevalence of histologically proven LC was 13{\%}, and among those with LC-IPF cumulative incidence at 1 and 3 years was 41{\%} and 82{\%}. Patients with LC were more frequently smokers (91.3{\%} vs 71.6{\%}, P = .001), with combined pulmonary fibrosis and emphysema (52{\%} vs 32{\%}, P = .052). Survival in patients with LC-IPF was significantly worse than in patients with IPF without LC (median survival, 38.7 months vs 63.9 months; hazard ratio = 5.0; 95{\%} CI, 2.91-8.57; P <.001). Causes of death in the study group were respiratory failure in 43{\%} of patients, LC progression in 13{\%}, and LC treatment-related complications in 17{\%}. Conclusions: In patients with IPF, LC has a significant adverse impact on survival. Diagnosis and treatment of LC in IPF are burdened by an increased incidence of severe complicating events, apparently as lethal as the cancer itself.",
author = "Sara Tomassetti and Christian Gurioli and Ryu, {Jay H.} and Decker, {Paul A.} and Claudia Ravaglia and Paola Tantalocco and Matteo Buccioli and Sara Piciucchi and Nicola Sverzellati and Alessandra Dubini and Giampaolo Gavelli and Marco Chilosi and Venerino Poletti",
year = "2015",
month = "1",
day = "1",
doi = "10.1378/chest.14-0359",
language = "English",
volume = "147",
pages = "157--164",
journal = "Chest",
issn = "0012-3692",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The impact of lung cancer on survival of idiopathic pulmonary fibrosis

AU - Tomassetti, Sara

AU - Gurioli, Christian

AU - Ryu, Jay H.

AU - Decker, Paul A.

AU - Ravaglia, Claudia

AU - Tantalocco, Paola

AU - Buccioli, Matteo

AU - Piciucchi, Sara

AU - Sverzellati, Nicola

AU - Dubini, Alessandra

AU - Gavelli, Giampaolo

AU - Chilosi, Marco

AU - Poletti, Venerino

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Lung cancer (LC) is frequently associated with idiopathic pulmonary fibrosis (IPF). Despite this well-known association, the outcome of LC in patients with IPF is unclear. The objective of this study was to evaluate the impact of LC on survival of patients with associated IPF. Methods: A total of 260 patients with IPF were reviewed, and 186 IPF cases had complete clinical and follow-up data. Among these, five cases were excluded because LC was radiologically suspected but not histologically proven. The remaining 181 cases were categorized in two groups: 23 patients with biopsy-proven LC and IPF (LC-IPF) and 158 patients with IPF only (IPF). Survival and clinical characteristics of the two groups were compared. Results: Prevalence of histologically proven LC was 13%, and among those with LC-IPF cumulative incidence at 1 and 3 years was 41% and 82%. Patients with LC were more frequently smokers (91.3% vs 71.6%, P = .001), with combined pulmonary fibrosis and emphysema (52% vs 32%, P = .052). Survival in patients with LC-IPF was significantly worse than in patients with IPF without LC (median survival, 38.7 months vs 63.9 months; hazard ratio = 5.0; 95% CI, 2.91-8.57; P <.001). Causes of death in the study group were respiratory failure in 43% of patients, LC progression in 13%, and LC treatment-related complications in 17%. Conclusions: In patients with IPF, LC has a significant adverse impact on survival. Diagnosis and treatment of LC in IPF are burdened by an increased incidence of severe complicating events, apparently as lethal as the cancer itself.

AB - Background: Lung cancer (LC) is frequently associated with idiopathic pulmonary fibrosis (IPF). Despite this well-known association, the outcome of LC in patients with IPF is unclear. The objective of this study was to evaluate the impact of LC on survival of patients with associated IPF. Methods: A total of 260 patients with IPF were reviewed, and 186 IPF cases had complete clinical and follow-up data. Among these, five cases were excluded because LC was radiologically suspected but not histologically proven. The remaining 181 cases were categorized in two groups: 23 patients with biopsy-proven LC and IPF (LC-IPF) and 158 patients with IPF only (IPF). Survival and clinical characteristics of the two groups were compared. Results: Prevalence of histologically proven LC was 13%, and among those with LC-IPF cumulative incidence at 1 and 3 years was 41% and 82%. Patients with LC were more frequently smokers (91.3% vs 71.6%, P = .001), with combined pulmonary fibrosis and emphysema (52% vs 32%, P = .052). Survival in patients with LC-IPF was significantly worse than in patients with IPF without LC (median survival, 38.7 months vs 63.9 months; hazard ratio = 5.0; 95% CI, 2.91-8.57; P <.001). Causes of death in the study group were respiratory failure in 43% of patients, LC progression in 13%, and LC treatment-related complications in 17%. Conclusions: In patients with IPF, LC has a significant adverse impact on survival. Diagnosis and treatment of LC in IPF are burdened by an increased incidence of severe complicating events, apparently as lethal as the cancer itself.

UR - http://www.scopus.com/inward/record.url?scp=84920735730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920735730&partnerID=8YFLogxK

U2 - 10.1378/chest.14-0359

DO - 10.1378/chest.14-0359

M3 - Article

C2 - 25166895

AN - SCOPUS:84920735730

VL - 147

SP - 157

EP - 164

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -